The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ

Neurology

Volumn 61, Issue 9 SUPPL. 5, 2003, Pages

  Pachner, Andrew R ^a   Oger, Joel ^b   Palace, Jacqueline ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA INTERFERON ANTIBODY; BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTIGENICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATIENT MONITORING; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION;

EID: 0242571616     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000092359.93813.92     Document Type: Conference Paper

References (5)

1. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β. J Immunol Methods 1999;227:121-135.
2. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
3. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-1279.
4. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients. Neurology 2003 (in press).
5. Lawrence N, Oger J, Aziz T, Palace J, Vincent A. A radioimmunoprecipitation assay for binding IFNb1b antibodies: comparison with neutralising antibodies in predicting clinical outcome. J Neurol Neurosurg Psychiatry 2003;74:1-4.